Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 1;108(12):2336-2350.
doi: 10.1097/TP.0000000000005056. Epub 2024 May 21.

Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion

Kymberly D Watt  1 , Stacey Rolak  1 , David P Foley  2 , Jennifer K Plichta  3 , Sandhya Pruthi  1 , Deborah Farr  4 , Fiona O Zwald  5 , Richard D Carvajal  6 , Arkadiusz Z Dudek  1 , Cristina B Sanger  2   7 , Ricciardi Rocco  8 , George J Chang  9 , Don S Dizon  10 , Carrie L Langstraat  11 , Deanna Teoh  12 , Piyush K Agarwal  13 , Talal Al-Qaoud  14 , Scott Eggener  13 , Cassie C Kennedy  1 , Jonathan D'Cunha  15 , Nisha A Mohindra  16 , Shelby Stewart  17 , Thomas H Habermann  1 , Stephen Schuster  18 , Matthew Lunning  19 , Nirav N Shah  20 , Morie A Gertz  1 , Jayesh Mehta  16 , Attaya Suvannasankha  21 , Elizabeth Verna  22 , Maryjane Farr  23 , Christopher D Blosser  24 , Laura Hammel  25 , David P Al-Adra  2
Affiliations
Review

Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion

Kymberly D Watt et al. Transplantation. .

Abstract

With improved medical treatments, the prognosis for many malignancies has improved, and more patients are presenting for transplant evaluation with a history of treated cancer. Solid organ transplant (SOT) recipients with a prior malignancy are at higher risk of posttransplant recurrence or de novo malignancy, and they may require a cancer surveillance program that is individualized to their specific needs. There is a dearth of literature on optimal surveillance strategies specific to SOT recipients. A working group of transplant physicians and cancer-specific specialists met to provide expert opinion recommendations on optimal cancer surveillance after transplantation for patients with a history of malignancy. Surveillance strategies provided are mainly based on general population recurrence risk data, immunosuppression effects, and limited transplant-specific data and should be considered expert opinion based on current knowledge. Prospective studies of cancer-specific surveillance models in SOT recipients should be supported to inform posttransplant management of this high-risk population.

PubMed Disclaimer

Conflict of interest statement

The authors declare no funding or conflicts of interest.

References

    1. Engels EA. Cancer in solid organ transplant recipients: there is still much to learn and do. Am J Transplant. 2017;17:1967–1969.
    1. Acuna SA, Huang JW, Scott AL, et al. Cancer screening recommendations for solid organ transplant recipients: a systematic review of clinical practice guidelines. Am J Transplant. 2017;17:103–114.
    1. Al-Adra DP, Hammel L, Roberts J, et al. Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: a consensus expert opinion statement. Am J Transplant. 2021;21:475–483.
    1. Al-Adra DP, Hammel L, Roberts J, et al. Pre-transplant solid organ malignancy and organ transplant candidacy: a consensus expert opinion statement. Am J Transplant. 2021;21:460–474.
    1. Livingston-Rosanoff D, Foley DP, Leverson G, et al. Impact of pre-transplant malignancy on outcomes after kidney transplantation: United Network for Organ Sharing database analysis. J Am Coll Surg. 2019;229:568–579.

Publication types

Substances